196 related articles for article (PubMed ID: 9678192)
1. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity.
Näslund E; Backman L; Holst JJ; Theodorsson E; Hellström PM
Obes Surg; 1998 Jun; 8(3):253-60. PubMed ID: 9678192
[TBL] [Abstract][Full Text] [Related]
2. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
3. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
[TBL] [Abstract][Full Text] [Related]
4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
5. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
6. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
7. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity.
Näslund E; Grybäck P; Hellström PM; Jacobsson H; Holst JJ; Theodorsson E; Backman L
Int J Obes Relat Metab Disord; 1997 May; 21(5):387-92. PubMed ID: 9152741
[TBL] [Abstract][Full Text] [Related]
9. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
[TBL] [Abstract][Full Text] [Related]
10. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity.
Ranganath LR; Beety JM; Morgan LM
Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081
[TBL] [Abstract][Full Text] [Related]
12. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
Fukase N; Igarashi M; Takahashi H; Manaka H; Yamatani K; Daimon M; Tominaga M; Sasaki H
Diabet Med; 1993; 10(1):44-9. PubMed ID: 8435987
[TBL] [Abstract][Full Text] [Related]
13. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.
Orskov C; Wettergren A; Holst JJ
Scand J Gastroenterol; 1996 Jul; 31(7):665-70. PubMed ID: 8819215
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic greater curvature plication in morbidly obese women with type 2 diabetes: effects on glucose homeostasis, postprandial triglyceridemia and selected gut hormones.
Bradnova O; Kyrou I; Hainer V; Vcelak J; Halkova T; Sramkova P; Dolezalova K; Fried M; McTernan P; Kumar S; Hill M; Kunesova M; Bendlova B; Vrbikova J
Obes Surg; 2014 May; 24(5):718-26. PubMed ID: 24307436
[TBL] [Abstract][Full Text] [Related]
15. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
17. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
[TBL] [Abstract][Full Text] [Related]
18. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
19. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
Carr RD; Larsen MO; Jelic K; Lindgren O; Vikman J; Holst JJ; Deacon CF; Ahrén B
J Clin Endocrinol Metab; 2010 Feb; 95(2):872-8. PubMed ID: 20008019
[TBL] [Abstract][Full Text] [Related]
20. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
